x

Posted 10 October, 2023

Silk Road Medical Inc appointed new CEO

CEO Change detected for ticker Nasdaq:SILK in a 8-K filed on 10 October, 2023.


  On October 10, 2023, after serving as the Company's President and Chief Executive Officer ("CEO") for over 11 years, Erica J. Rogers informed the Company and its Board of Directors (the "Board") of her plans to retire from the Company following the completion of a succession process.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Silk Road Medical Inc
Health Care/Life Sciences • Medical Equipment/Supplies
Silk Road Medical, Inc. engages in the development and manufacturing of medical devices to treat neurovascular diseases. Its products include ENROUTE transcarotid neuroprotection system, ENROUTE transcarotid stent system, and ENROUTE transcarotid peripheral access kit. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.
Market Cap
$695M
View Company Details
Relevant filing section
Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On October 10, 2023, after serving as the Company's President and Chief Executive Officer ("CEO") for over 11 years, Erica J. Rogers informed the Company and its Board of Directors (the "Board") of her plans to retire from the Company following the completion of a succession process. The Company is working with an executive search firm. To ensure a smooth transition, Ms. Rogers will remain at the Company and continue to serve as CEO and as a Board member until the effective date of the Board's appointment of her successor. Ms. Rogers's plans to retire are for personal reasons and not because of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.